Elder Pharma bags suitability certificate from EDQM for Diosmin
The move is expected to increase the global market share of Elder Pharma.
New Delhi, November 6, 2012: Elder Pharmaceuticals today announced that the company has secured certificate of suitability for Diosmin API from the European drug authority. It may be noted here that the drug is used for the treatment related to veins.
"The recognition by EDQM shall immensely help the company to further enter the regulated markets of European Union," said Alok Saxena, Joint Managing Director, Elder Pharmaceuticals.
Diosmin is an oral phlebotropic drug which is used in the treatment of the venous system related diseases including Chronic Venous insufficiency and Hemorrhoidal disease.
The global market size of the drug is around US$ 500 million of which the European markets account for about US$ 255 million.
Elder Pharma already has consumers in regions like Southeast Asia, Africa and Latin America and It is expected that the certificate from EQDM will help the Indian drug firm to expand its global market share by increase its reach in Europe.